Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren/HCTZ in Aliskiren-Refractory Hypertension
NCT00386139Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aliskiren and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by Novartis. Primary endpoint: Mean Sitting Diastolic Blood Pressure at 8 weeks. Started Sep 2006; status: completed.
02
Drugs
aliskirenhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00386139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386139.